|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to human Trag-3.|
|Purification||Ammonium sulfate precipitation|
|Contains||0.08% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This protein is expressed in various tumor cell lines including carcinomas, myeloid or lymphoid malignancies, melanomas or prostate cancer. It is also weakly expressed in kidney and overexpressed in taxol-resistant breast cancer line MDA 435(TR) or the doxorubicin-resistant multiple myelanoma lines 8226/Dox(40) or 8226/MDR(10)V.1.
The expression of the cancer-testis antigen Taxol resistanceassociated gene-3 (TRAG-3) is associated with acquired paclitaxel (Taxol) resistance, and is expressed in a variety of cancers - e.g., breast cancer, leukemia, and melanoma. Overexpressed in taxolresistant breast cancer line MDA 435(TR) and the doxorubicinresistant multiple myelanoma lines 8226/Dox(40) and 8226/MDR (10)V. Weakly expressed in kidney. TRAG-3 is an attractive target for immunotherapy of cancer.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.